🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

11,276 results for “Te” Clear

  1. Eplerenone

    Pfizer

    Hypertension

    phase 3 small molecule completed

    2 trials

  2. Eplontersen

    IONIS PHARMACEUTICALS INC

    Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

    phase 3 small molecule active

    1 trial

  3. Eplontersen

    IONIS PHARMACEUTICALS INC

    Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

    phase 3 small molecule active

    2 trials

  4. Epoetin alga (Epogen)/vadadustat

    Akebia Europe Limited

    Anemia Associated With Chronic Kidney Disease

    phase 3 small molecule active

    1 trial

  5. Erbitux 5 mg/mL solution for infusion, Ficlatuzumab, Ficlatuzumab, The corresponding placebo for this study is 0.9% Sodium Chloride injection for intravenous administration and this will be provided by the study site (and reimbursed by the Sponsor).

    Lacuna Pharma Pty Ltd

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 3 small molecule active

    1 trial

  6. Erbitux 5 mg/mL solution for infusion, JNJ-61186372, Erbitux 5 mg/mL solution for infusion, VEGZELMA 25 mg/mL concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion., BEVACIZUMAB

    Janssen-Cilag International N.V.

    KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  7. Erenumab

    United Therapeutics Europe Ltd

    Fibromyalgia

    phase 3 small molecule terminated

    1 trial

  8. Eribulin Mesylate

    United Therapeutics Europe Ltd

    Breast Adenocarcinoma

    phase 3 small molecule on hold

    1 trial

  9. Erleada 240 mg film-coated tablets, Erleada 60 mg film-coated tablets, Docetaxel AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Disc Medicine

    Metastatic hormone-sensitive prostate cancer

    phase 3 small molecule active

    1 trial

  10. Ertapenem

    Iterum Therapeutics plc

    Intra Abdominal Infections

    phase 3 small molecule completed

    1 trial

  11. EryDex Low dose DSP

    Quince Therapeutics

    Nervous System Disease

    phase 3 small molecule completed

    1 trial

  12. EryDex System

    Quince Therapeutics

    Ataxia Telangiectasia

    phase 3 other terminated

    1 trial

  13. Erythropoiesis-Stimulating Agent (ESA)

    Akebia Europe Limited

    Anemia of Chronic Kidney Disease

    phase 3 small molecule active

    1 trial

  14. Escitalopram

    Otsuka Beijing Research Institute

    Major Depressive Disorder (MDD)

    phase 3 small molecule terminated

    1 trial

  15. Escitalopram

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Mild-to-moderate Depression

    phase 3 small molecule completed

    1 trial

  16. Esketamine

    Janssen Cilag International NV

    Depressive Disorder, Major

    phase 3 small molecule completed

    1 trial

  17. Eslicarbazepine acetate (BIA 2-093)

    Bial Portela & Companhia S.A.

    Partial Epilepsy in Children and Adolescents

    phase 3 small molecule completed

    1 trial

  18. Estradiol

    Teva Pharma GmbH

    Dyspareunia

    phase 3 small molecule completed

    1 trial

  19. Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)

    Bayer HealthCare AG

    Primary Dysmenorrhea

    phase 3 small molecule completed

    1 trial

  20. EstroTep 500 MBq/mL, solution injectable

    The George Institute

    Women with ER+ HER2- metastatic breast cancer who progressed on first line therapy with CDK4/6 inhibitor and aromatase inhibitor

    phase 3 small molecule active

    1 trial

  21. Etavopivat A 100 mg, Etavopivat placebo., Etavopivat A 200 mg

    NovoThirteen

    sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  22. Etavopivat A 200 mg

    NovoThirteen

    Sickle Cell Disease and Thalassaemia

    phase 3 small molecule active

    1 trial

  23. Etelcalcetide

    Amgen

    Hyperparathyroidism, Secondary

    phase 3 small molecule completed

    1 trial

  24. Etelcalcetide

    Amgen

    Secondary Hyperparathyroidism

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources